Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer

por Stein, Alexander, Atanackovic, Djordje, Hildebrandt, Bert, Stübs, Patrick, Brugger, Wolfram, Hapke, Gunnar, Steffens, Claus-Christoph, Illerhaus, Gerald, Bluemner, Ernst, Stöhlmacher, Jan, Bokemeyer, Carsten
Publicado 2015